Study of Efficacy and Safety of Laparoscopic Intra-abdominal Chemotherapy (PIPAC) Performed in Patients With Peritoneal Carcinomatosis From Colorectal, Ovarian, Gastric Cancer and Primary Peritoneal Tumors

Inclusion Criteria: * Clinical and pathological confirmation of peritoneal carcinomatosis from gastric, colorectal and ovarian cancers or primary peritoneal tumors. * Patients aged between 18 and 78 years. * Performance status sec. ECOG ≤ 2 * Disease progression/relapse after at least one line of previous i.v. standard chemotherapy in gastric cancer and primary peritoneal tumors and two lines in colorectal and ovarian cancers. * Patients with peritoneal carcinomatosis from ovarian, gastric and colorectal cancers and primary peritoneal cancers not eligible to cytoreductive surgery +/- HIPEC. * Blood and electrolyte counts, liver, renal and cardiopulmonary function parameters within 10% of the normal range. * Written informed consent. * Tumor mass present on CT-scan in order to allow tumor response assessment with RECIST-criteria. Exclusion Criteria: * Extra-abdominal metastatic disease, with the exception of isolated pleural carcinomatosis. * Bowel obstruction. * Severe renal impairment, myelosuppression, severe hepatic impairment, severe myocardial insufficiency, recent myocardial infarction, severe arrhythmias. * Immunocompromised patients such as those with an immunosuppressive medication or a known disease of the immune system. * Creatinine clearance \< 60 ml /min. * Pregnancy. * Previous treatment reaching the maximum cumulative dose of doxorubicin, daunorubicin, epirubicin, idarubicin and/or other anthracyclines and anthracenediones. * Known allergy to cisplatin or other platinum-containing compounds or to doxorubicin. * Patients of both sexes who do not conduct complete abstinence from heterosexual relationships or agree to use an effective clinically acceptable method (with failure rate \<1%) during the study and the following 6 months after the last treatment.